Pages
- About Us
- Basket
- Careers
- Case Studies
- Chemistry
- Collaborative Drug Discovery
- Consultancy
- Contribute Content
- Drug Discovery Services
- DUB focused research programmes
- Home Page
- Home Page New
- Keep Me Updated
- News and Events
- Privacy Policy
- Products
- Research Tools
- Resources
- Site Map
- Temp CSV
- Test Run Colab Page
- The Ubiquitin System
- Video
- Website Acceptable Use Policy
- Website Cookies Policy
- Website Terms of Use Policy
- Working With Us
- OTU Family
Posts by category
- Category: Uncategorized
- Category: News
- Rapid Identification of Redox Cycling Compounds – REDOXprofiler™
- Ubiquigent awarded Innovate UK grant, closes further round of investment and strengthens management team
- Ubiquigent and Forma Therapeutics enter an exclusive R&D collaboration to develop novel DUB inhibitors
- Use of Ubiquigent’s DUBprofiler™ services in key 2017 publications
- Ubiquigent awarded Innovate UK grant
- Ubiquigent launches first novel compound library
- Horizon & Ubiquigent Enter into Collaboration Agreement
- Dundee, UK – the place to access world class ubiquitin system research expertise and capabilities
- Ubiquigent Strengthens Team to Deliver Cutting Edge Drug Discovery Services, Research Tools and Chemistry and Announces Launch of New Website
- Ubiquigent and Cyclofluidic Enter into Collaboration to Build Novel Ubiquitin System Targeted Compound Libraries
- Exclusive collaboration with UbiQ to commercialise novel reagents for Parkinson’s Disease research
- Dr Achim Werner awarded the Ubiquigent Young Scientist Prize
- Ubiquigent and University of Dundee announce collaboration to develop novel ubiquitin system targeted compound libraries
- Ubiquigent announces £0.5m funding and strengthens board of directors with key appointment
- Ubiquigent Ltd announces the appointment of Cosmo Bio USA Inc as their sole north American product distributor
- Ubiquigent Ltd announces expansion of its DUBprofiler™ service
- Harvard Medical School’s Prof. Alfred Goldberg delivers inaugural speech
- Stemgent announces formation of Ubiquigent, a new UK-listed biotechnology company based in Dundee, Scotland
- Category: Events
- CHI Drug Discovery Chemistry, San Diego 8-12th April
- European Protein Degradation Congress, 22nd-23rd May, Basel.
- Targeted Protein Degradation, 24th – 25th October, Boston
- 2018 BIO International Convention
- CHI Drug Discovery Chemistry, San Diego 5th April
- ELRIG networking event
- Enzymes in Drug Discovery Summit
- BioEurope Berlin
- 15th Annual Discovery on Target
- SCI: Targeting the Ubiquitin-Proteasome Pathway (19th May 2017)
- Ubiquigent attending Bio Europe 2016 – Cologne, Germany (7th-9th Nov)
- Targeted chemical libraries: the keys to unlock the ubiquitin system
- 6th GTC Ubiquitin research and drug discovery meeting
- Ubiquitin Signaling with NF-kappaB and MAP Kinase Signaling in Inflammation
Resources
- Featured Publications of Interest
- Ubiquitin/Ubl System Related and Other Reference Websites
- Ubiquigent Produced Videos
- April 2015: PINK1-Parkin products
- April 2015: Phospho-Ubiquitin products
- January 2015: Cullin Ring Ligase (CRL) products
- Summer 2014: Targeted Chemical Libraries
- February 2014: UBIQUInews; Edition Number 1
- Validation and Utility of the Ubiselect™ Kit
- Validation and Experimental Utility of the DUBscan™ Kit
- Validation and Experimental Utility of the E2scan™ Kit v2
- Other Sources